Similar articles for PMID: 30396964

Year	Number of Results
2000	1
2001	3
2002	1
2003	5
2004	6
2005	8
2006	8
2007	5
2008	8
2009	5
2010	10
2011	1
2012	1
2013	1
2014	3
2015	3
2016	5
2017	9
2018	6
2019	4
2020	2
2021	3
2022	3
2023	1
2024	0

1

Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.

Bendardaf R, Sharif-Askari FS, Sharif-Askari NS, Syrjänen K, Pyrhönen S. Bendardaf R, et al. Anticancer Res. 2018 Nov;38(11):6399-6404. doi: 10.21873/anticanres.13000. Anticancer Res. 2018. PMID: 30396964

2

Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.

Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S. Bendardaf R, et al. Tumour Biol. 2007;28(4):212-20. doi: 10.1159/000107417. Epub 2007 Aug 24. Tumour Biol. 2007. PMID: 17717427

3

Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.

Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S. Bendardaf R, et al. Acta Oncol. 2008;47(6):1046-53. doi: 10.1080/02841860701678753. Acta Oncol. 2008. PMID: 17943475

4

Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer.

Bendardaf R, Sharif-Askari FS, Sharif-Askari NS, Syrjänen K, Pyrhönen S. Bendardaf R, et al. Anticancer Res. 2019 Apr;39(4):1953-1957. doi: 10.21873/anticanres.13305. Anticancer Res. 2019. PMID: 30952738

5

Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.

Kim JE, Hong YS, Ryu MH, Lee JL, Chang HM, Lim SB, Kim JH, Jang SJ, Kim MJ, Yu CS, Kang YK, Kim JC, Kim TW. Kim JE, et al. Cancer Sci. 2011 Sep;102(9):1706-11. doi: 10.1111/j.1349-7006.2011.02009.x. Epub 2011 Jul 12. Cancer Sci. 2011. PMID: 21679278 Free article.

6

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M. Bertagnolli MM, et al. J Clin Oncol. 2009 Apr 10;27(11):1814-21. doi: 10.1200/JCO.2008.18.2071. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273709 Free PMC article. Clinical Trial.

7

Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.

Ma J, Zhang Y, Shen H, Kapesa L, Liu W, Zeng M, Zeng S. Ma J, et al. Tumour Biol. 2015 Dec;36(12):9599-609. doi: 10.1007/s13277-015-3723-5. Epub 2015 Jul 5. Tumour Biol. 2015. PMID: 26142736

8

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

Cohen R, Buhard O, Cervera P, Hain E, Dumont S, Bardier A, Bachet JB, Gornet JM, Lopez-Trabada D, Dumont S, Kaci R, Bertheau P, Renaud F, Bibeau F, Parc Y, Vernerey D, Duval A, Svrcek M, André T. Cohen R, et al. Eur J Cancer. 2017 Nov;86:266-274. doi: 10.1016/j.ejca.2017.09.022. Epub 2017 Oct 19. Eur J Cancer. 2017. PMID: 29055842

9

Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer.

Bendardaf R, Lamlum H, Ristamäki R, Syrjänen K, Pyrhönen S. Bendardaf R, et al. Oncol Rep. 2008 Nov;20(5):999-1004. Oncol Rep. 2008. PMID: 18949393

10

Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.

Yuuki S, Komatsu Y, Fuse N, Kato T, Miyagishima T, Kudo M, Watanabe M, Tateyama M, Kunieda Y, Wakahama O, Sakata Y, Asaka M. Yuuki S, et al. Clin Drug Investig. 2010;30(4):243-9. doi: 10.2165/11534470-000000000-00000. Clin Drug Investig. 2010. PMID: 20225907 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

92 results

Results by year